All-trans retinoic acid added to treatment of primary immune thrombocytopenia: a systematic review and meta-analysis

Yang, Jinjun; Zhao, Lei; Wang, Wen; Wu, Yu

doi:10.1007/s00277-023-05263-w

Cited by 1 publication

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wu YJ et al ( Wu et al, 2022 ) randomized ITP patients in a 2:1 ratio, with 112 patients receiving low-dose rituximab (LD-RTX) (100 mg qw for a total of 6 weeks) + ATRA (20 mg/m 2 for 12 weeks), and 56 receiving LD-RTX monotherapy; there was an overall response of 80% in the LD-RTX + ATRA group compared to 59% in the LD-RTX 59% in the monotherapy group. ATRA significantly improves initial and long-term responses in patients with ITP and is associated with reduced rates of relapse and salvage therapy, with the main adverse effects being dry skin, dizziness, headache, and acne-like rashes ( Yang et al, 2023 ). ATRA has provided a new boon in the treatment of ITP patients.…”

Section: Non-malignant Hematologic Diseasesmentioning

confidence: 99%

All-trans retinoic acid in hematologic disorders: not just acute promyelocytic leukemia

Chen,

Tong,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

All-trans retinoic acid (ATRA) plays a role in tissue development, neural function, reproduction, vision, cell growth and differentiation, tumor immunity, and apoptosis. ATRA can act by inducing autophagic signaling, angiogenesis, cell differentiation, apoptosis, and immune function. In the blood system ATRA was first used with great success in acute promyelocytic leukemia (APL), where ATRA differentiated leukemia cells into mature granulocytes. ATRA can play a role not only in APL, but may also play a role in other hematologic diseases such as immune thrombocytopenia (ITP), myelodysplastic syndromes (MDS), non-APL acute myeloid leukemia (AML), aplastic anemia (AA), multiple myeloma (MM), etc., especially by regulating mesenchymal stem cells and regulatory T cells for the treatment of ITP. ATRA can also increase the expression of CD38 expressed by tumor cells, thus improving the efficacy of daratumumab and CD38-CART. In this review, we focus on the mechanism of action of ATRA, its role in various hematologic diseases, drug combinations, and ongoing clinical trials.

show abstract

Section: Non-malignant Hematologic Diseasesmentioning

confidence: 99%